Embolx
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $250k | Seed | |
N/A | - | ||
N/A | - | ||
$2.0m | Grant | ||
N/A | N/A | Seed | |
Total Funding | €2.0m |
Recent News about Embolx
EditEmbolx is an emerging commercial stage medical device company based in Silicon Valley, specializing in the development of advanced microcatheters for arterial embolization procedures. The company's flagship product, the Sniper balloon occlusion microcatheter, sets a new standard in the field by enabling precise embolic delivery and superior target filling. This is achieved through the control of pressure to direct blood flow while simultaneously protecting non-target surrounding tissues.
Embolx primarily serves interventional radiologists and oncologists who perform minimally invasive procedures to treat conditions such as prostate artery embolization (PAE), hepatocellular carcinoma (HCC), and other vascular anomalies. Operating within the medical device market, Embolx leverages its innovative technology to address the growing demand for more effective and safer embolization techniques.
The company's business model revolves around the commercialization of its proprietary microcatheter technology. Revenue is generated through the sale of these specialized medical devices to hospitals, clinics, and medical centers globally. By attending key industry conferences and collaborating with leading medical professionals, Embolx continues to expand its market presence and drive adoption of its products.
Keywords: microcatheters, arterial embolization, Sniper, balloon occlusion, interventional radiology, oncology, minimally invasive, medical devices, Silicon Valley, embolic delivery.